5 December 2019 - While there is no question that falling prices that come with competition are cause for optimism in the United States, which is burdened by rising drug costs, some experts from Europe caution that a focus on price alone misses key reasons to use biosimilars.

In the United States, discussions about the utility of biosimilars in the healthcare system have been squarely focused on price. 

List price discounts announced alongside product launches have been the cause for debate as stakeholders attempt to make the most sustainable decisions for their health systems and for patients, and while there is no question that falling prices that come with competition are cause for optimism in a nation burdened by rising costs, some experts from Europe caution that a focus on price alone misses key reasons to use biosimilars.

Read Center for Biosimilars article